- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07742150
Placebo Effect in Field-Based Physical Performance
31. Juli 2026 aktualisiert von: Poznan University of Physical Education
Psychophysiological Mechanisms of the Placebo Effect on Physical Performance in Field Settings
This study aims to investigate the placebo (PLA) effect on physical performance across different sports disciplines in real-world, field-based settings.
The study investigates how participant expectations and beliefs regarding caffeine (CAF) intake influence physical performance and psychomotor function outside the controlled laboratory environment.
Healthy, physically active adults (n = 120) from diverse sports backgrounds will be randomly assigned to receive caffeine, placebo, or no intervention.
Participants will perform discipline-specific field exercise tests (e.g., running-based protocols or repeated sprint protocols) while physiological responses are monitored using wearable technology.
Physical performance outcomes and psychomotor responses will be analyzed to evaluate the real-world impact of the placebo effect and to distinguish the pharmacological effects of caffeine from those driven by psychological expectations across different athletic settings.
Studienübersicht
Status
Noch keine Rekrutierung
Intervention / Behandlung
Detaillierte Beschreibung
This study employs a cross-sectional design conducted in diverse field settings to investigate the placebo (PLA) effect across different sports disciplines.
Participants (n = 120, aged 20-35 years) representing different training profiles (endurance and mixed) will be randomly assigned to one of three parallel groups: Caffeine, Placebo, or Control.
Each participant will complete a single experimental session lasting approximately 35 minutes, consisting of: (1) baseline psychomotor assessment using the Simple Reaction Time test, (2) a discipline-specific exercise protocol (e.g., the Cooper test performed on an athletics track or a Repeated Sprint Ability protocol), and (3) post-exercise recovery monitoring.
Physiological parameters, including heart rate (HR), heart rate variability (HRV), and respiratory rate (RR), together with postural stability, will be continuously monitored using wearable technology.
The study will evaluate how psychological expectations influence physical performance, psychomotor function, and physiological responses during sport-specific exercise, providing evidence for the role of the placebo effect under real-world athletic conditions.
Studientyp
Interventionell
Einschreibung (Geschätzt)
120
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Jakub Malik, PhD
- Telefonnummer: +48739975701
- E-Mail: malik@awf.poznan.pl
Studienorte
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polen
- Poznań University of Physical Education
-
Kontakt:
- Jakub Malik, PhD
- Telefonnummer: +48739975701
- E-Mail: malik@awf.poznan.pl
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Ja
Beschreibung
Inclusion Criteria:
- Age between 20 and 35 years,
- Healthy adults,
- Regular physical activity,
- Normal or corrected-to-normal vision,
- Habitual caffeine consumption.
Exclusion Criteria:
- History of neurological, psychiatric, cardiovascular, or metabolic disorders,
- Current use of medication or supplements affecting the central nervous system,
- Musculoskeletal injuries that would impair physical performance,
- No habitual caffeine consumption or severe negative side effects of caffeine,
- Diagnosed sleep disorders or chronic fatigue,
- Diagnosed major depressive disorder or other severe psychiatric conditions,
- Presence of any menstrual disorders,
- Inability to attend all experimental study visits.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Caffeine Group
Participants ingest a single dose of caffeine (6mg/kg body mass) prior to a field-based exercise protocol (e.g., Cooper test or Repeated Sprint Ability).
|
Anhydrous caffeine administered in an encapsulated form at a dosage of 6mg per kilogram of body mass, 30-60 minutes before the exercise protocol.
|
|
Aktiver Komparator: Placebo Group
Participants ingest a single dose of placebo (corn starch) in an identical capsule prior to a field-based exercise protocol.
|
Corn starch administered in an identical encapsulated form as the active caffeine, 30-60 minutes before the exercise protocol.
|
|
Schein-Komparator: Control Group
Participants perform the same field-based exercise protocol without ingesting any capsule or active substance.
|
Participants perform the same exercise protocols without any capsule or substance administration.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Physical Performance Capacity (total distance in running, metres)
Zeitfenster: Measured during the exercise protocol immediately following administration of the study intervention.
|
Total physical work capacity measured as the total running distance (metres) completed during the standardized exercise protocol.
|
Measured during the exercise protocol immediately following administration of the study intervention.
|
|
Physical Performance Capacity (total work in Joules for cycling)
Zeitfenster: Measured during the exercise protocol immediately following administration of the study intervention.
|
Total physical work capacity measured as the total mechanical work (Joules) completed during the standardized cycling exercise protocol.
|
Measured during the exercise protocol immediately following administration of the study intervention.
|
|
Physical Performance Capacity (exercise duration until exhaustion, minutes)
Zeitfenster: Measured during the exercise protocol immediately following administration of the study intervention.
|
Total physical work capacity measured as exercise duration until volitional exhaustion during the standardized exercise protocol.
|
Measured during the exercise protocol immediately following administration of the study intervention.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Exercise Heart Rate (bpm)
Zeitfenster: Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
Heart rate (beats per minute) recorded continuously throughout the standardized exercise protocol.
|
Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
|
Cognitive Heart Rate (bpm)
Zeitfenster: Measured during cognitive testing immediately before and immediately after the exercise protocol.
|
Heart rate recorded during standardized cognitive performance tasks.
|
Measured during cognitive testing immediately before and immediately after the exercise protocol.
|
|
Post-Exercise Heart Rate Recovery (bpm)
Zeitfenster: Continuously monitored during the first 5 minutes immediately following completion of the exercise protocol.
|
Heart rate recorded during the post-exercise recovery period.
|
Continuously monitored during the first 5 minutes immediately following completion of the exercise protocol.
|
|
Cognitive Reaction Time (ms)
Zeitfenster: Measured immediately before and immediately after the exercise protocol.
|
Reaction time measured during standardized cognitive tasks (e.g., Psychomotor Vigilance Test, Stroop Test, Flanker Test).
|
Measured immediately before and immediately after the exercise protocol.
|
|
Rating of Perceived Exertion (Borg Scale, points)
Zeitfenster: Measured immediately after completion of the exercise protocol.
|
Perceived exertion assessed using the Borg Rating of Perceived Exertion Scale (6-20).
|
Measured immediately after completion of the exercise protocol.
|
|
Biomechanical Kinematic Profile (cm)
Zeitfenster: Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
Continuous recording of kinematic parameters derived from wearable sensors, including step length and vertical oscillation.
|
Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
|
Biomechanical Kinematic Profile (ms)
Zeitfenster: Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
Continuous recording of stance time derived from wearable sensor data.
|
Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
|
Biomechanical Kinematic Profile (steps/min)
Zeitfenster: Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
Continuous recording of cadence derived from wearable sensor data.
|
Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
|
Anthropometric Indices (kg)
Zeitfenster: Measured at the start of the protocol.
|
Body mass expressed in kilograms.
|
Measured at the start of the protocol.
|
|
Anthropometric Indices (m)
Zeitfenster: Measured at the start of the protocol.
|
Height expressed in metres.
|
Measured at the start of the protocol.
|
|
Body composition (fat-free mass, fat mass) (kg)
Zeitfenster: Measured at the start of the protocol.
|
Assessment of body composition (fat-free mass, fat mass) (kg) will be performed at the start of the protocol.
|
Measured at the start of the protocol.
|
|
Body composition (fat-free mass, fat mass) (%)
Zeitfenster: Measured at the start of the protocol.
|
Assessment of body composition (fat-free mass, fat mass) (%) will be performed at the start of the protocol.
|
Measured at the start of the protocol.
|
|
Body composition (total body water) (L)
Zeitfenster: Measured at the start of the protocol.
|
Assessment of body composition (total body water) (L) will be performed at baseline at the start of the protocol.
|
Measured at the start of the protocol.
|
|
Body composition (total body water) (%)
Zeitfenster: Measured at the start of the protocol.
|
Assessment of body composition (total body water) (%) will be performed at baseline at the start of the protocol.
|
Measured at the start of the protocol.
|
|
Exercise Heart Rate Variability (ms)
Zeitfenster: Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
Heart rate variability recorded continuously throughout the standardized exercise protocol to assess autonomic regulation.
|
Continuously monitored during the exercise protocol immediately following administration of the study intervention.
|
|
Cognitive Heart Rate Variability (ms)
Zeitfenster: Measured during cognitive testing immediately before and immediately after the exercise protocol.
|
Heart rate variability recorded during standardized cognitive performance tasks.
|
Measured during cognitive testing immediately before and immediately after the exercise protocol.
|
|
Post-Exercise Heart Rate Variability Recovery (ms)
Zeitfenster: Continuously monitored during the first 5 minutes immediately following completion of the exercise protocol.
|
Heart rate variability recorded during the post-exercise recovery period.
|
Continuously monitored during the first 5 minutes immediately following completion of the exercise protocol.
|
|
Cognitive Accuracy (%)
Zeitfenster: Measured immediately before and immediately after the exercise protocol.
|
Accuracy measured during standardized cognitive tasks (e.g., Psychomotor Vigilance Test, Stroop Test, Flanker Test).
|
Measured immediately before and immediately after the exercise protocol.
|
|
Performance Expectancy (points)
Zeitfenster: Measured immediately after completion of the exercise protocol.
|
Measured immediately before the exercise protocol following administration of the study intervention.
|
Measured immediately after completion of the exercise protocol.
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Jakub Malik, PhD, Poznan University of Physical Education, Department of Sports Psychology
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. September 2026
Primärer Abschluss (Geschätzt)
31. März 2028
Studienabschluss (Geschätzt)
31. März 2029
Studienanmeldedaten
Zuerst eingereicht
21. Juli 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
31. Juli 2026
Zuerst gepostet (Tatsächlich)
3. August 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
3. August 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
31. Juli 2026
Zuletzt verifiziert
1. Juli 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 152-1-26
- 2025/57/N/NZ4/04470 (Andere Zuschuss-/Finanzierungsnummer: National Science Centre)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
UNENTSCHIEDEN
Beschreibung des IPD-Plans
The decision regarding the sharing of individual participant data has not yet been finalized.
We are currently evaluating the feasibility, ethical considerations, and data privacy requirements for potential data sharing.
A formal plan will be developed and implemented in accordance with institutional policies and regulatory standards upon the completion of the study.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .